Related Experiment Videos

Neurological syndromes of organophosphorus compounds

G A Jamal1

  • 1University Department of Neurology, Institute of Neurological Sciences, Southern General Hospital NHS Trust, Glasgow.

Adverse Drug Reactions and Toxicological Reviews
|August 1, 1997
PubMed

Insights

Organophosphorus compounds cause various neurological and psychiatric syndromes beyond acute poisoning. Current testing methods, like the hen test, are unreliable for detecting neurotoxicity, necessitating a reevaluation of pesticide safety assessments.

Area of Science:

  • Neurotoxicology
  • Environmental Health
  • Occupational Medicine

Background:

  • Organophosphorus (OP) compounds are known for acute cholinergic poisoning.
  • OPs can also induce subacute, delayed, and chronic neurological, neurobehavioral, and psychiatric syndromes.
  • These syndromes include intermediate syndrome, organophosphate-induced delayed neuropathy (OPIDN), and chronic organophosphate-induced neuropsychiatric disorder (COPIND).

Purpose of the Study:

  • To critically review the concept of neuropathy target esterase (NTE) inhibition and aging as a marker for OPIDN.
  • To evaluate the reliability of the hen test for screening OP neurotoxicity.
  • To describe the components and review evidence for the existence of COPIND.

Main Methods:

  • Critical literature review of existing concepts and studies.
  • Analysis of recent studies challenging the validity of the hen test.
  • Synthesis of evidence from case studies, disease clusters, and epidemiological investigations.

Main Results:

  • The hen test is an unreliable and flawed screening tool for OP neurotoxicity.
  • Recent studies demonstrate the unreliability of the hen test and underlying scientific concepts.
  • Evidence suggests the existence of COPIND, a syndrome with distinct neurological and psychiatric components.

Conclusions:

  • The current hen test is inadequate for identifying OPs as safe or "non-neurotoxic".
  • A new radical approach to pesticide neurotoxicity assessment is required before widespread use.
  • Further research is needed to define COPIND's profile, components, and clinical markers.

Related Concept Videos